Background: Intramuscular botulinum toxin injections are used for treatment of focal spasticity in children, particularly in those with a diagnosis of cerebral palsy. There are a variety of techniques used when performing botulinum toxin injections without clear standards for pediatric providers. Objective: To describe current practice techniques for botulinum toxin injections among pediatric physiatrists. Design: Cross-sectional survey using RedCap Software. Setting: Pediatric physiatrists who perform botulinum toxin injections. Participants: Survey of 307 pediatric physiatrists. Methods: Analysis of data from the 2017 practice survey of pediatric physiatrists in the United States. Main Outcome Measurements: Physicians were asked the primary botulinum toxin used, common dosing information, the role of localization, and the role of sedation and distraction in their practice. Results: Nearly all pediatric physiatrists use OnabotulinumtoxinA as the primary formulation of botulinum toxin. The maximum dose per body weight used per injection series had a median of 15 units/kilogram and a median maximum total dose of 500 units. Sixty-five percent of pediatric physiatrists report using sedation, of any type, for botulinum toxin injections. When using sedation, the most common primary method was general anesthesia (38.9%), followed by enteral or nasal anxiolytic with the patient awake (26.2%). The most common reported intended injection site for botulinum toxin was "in multiple sites spread throughout the muscle" (67.9%), and then "one site of the muscle at the motor point" (17.1%). Large muscles were injected using primarily anatomic guidance (75.6%) and electromyography (50.8%), and small muscles were primarily completed with electromyography (73.6%) and anatomic guidance (49.2%). Conclusion: There is considerable variability present in one common procedure performed by pediatric physiatrists. Level of Evidence: NA.
Introduction
Intramuscular botulinum toxin injections are used for treatment of focal spasticity in children, particularly in those with a diagnosis of cerebral palsy [1] [2] [3] [4] [5] [6] . The mechanism of action of botulinum toxin is to impede neuromuscular transmission by inhibiting the release of acetylcholine at the neuromuscular junction [7] . The intended outcomes from using botulinum toxin to manage spasticity are multidimensional and may include improved range of motion, increased functional independence, increased ease of care, and/or decreased pain [8] . There are currently 4 commercially available preparations of botulinum toxin A or B in the United States, although 7 serotypes are harvested from the obligate anaerobe Clostridium botulinum and are labeled A-G. The 4 preparations are OnabotulinumtoxinA (Botox; Allergan, Irvin, CA), AbobotulinumtoxinA (Dysport; Ipsen, Basking Ridge, NJ), RimabotulinumtoxinB (Myobloc; Solstice Neurosciences, Louisville, KY), and IncobotulinumtoxinA (Xeomin; Merz, Raleigh, NC) [9, 10] .
The clinical literature describes a number of different methods and techniques to perform botulinum toxin injections [11] . Common areas of variability in technique include the intended location within a muscle to inject, localization techniques used to identify the intended location, differing volume preparations or dilutions of botulinum toxin employed, as well as different practices for procedural sedation used when completing the procedure. Nearly all comparison literature for botulinum toxin injections has been published with adult subjects [12] [13] [14] [15] . There is a paucity of literature published about these techniques in the pediatric population [16] [17] [18] . Given the limitations of the literature regarding the treatment of spasticity with botulinum toxin in children and adolescents including the lack of information about the use of sedation, the objective of this project was to describe the current practice techniques when using botulinum toxin among pediatric physiatrists. We hypothesized that there is considerable variability in the techniques employed, including use of sedation, when completing the procedures.
Methods

Study Population
Three hundred twenty-one pediatric physiatrists were identified by searching the American Board of Physical Medicine & Rehabilitation listing (all physiatrists holding subspecialty certification in pediatric rehabilitation medicine [PRM]), contacting program directors of doubleboarding pediatrics/physical medicine and rehabilitation (PM&R) programs and PRM fellowships to identify alumni from these programs, and querying the PRM closed Facebook group. Individuals were considered to be pediatric physiatrists if they held PRM certification, trained in a double-boarded residency or fellowship, or practiced pediatric PM&R and identified themselves as a pediatric physiatrist. In the search process, 2 physicians were identified as retired, one requested not to have the survey sent, one identified themselves as not seeing children any longer, one was not practicing because of health reasons, and 14 did not have valid e-mail addresses. The final sample included 307 pediatric physiatrists.
Survey Instrument and Administration
The online survey was designed using RedCap software. The survey was delivered via e-mail with a link to the survey on April 1, 2017, to each of the 307 identified pediatric physiatrists. E-mail reminders and Facebook posts were sent to improve response rate. The Survey officially closed on May 22, 2017. Informed consent was obtained as part of the Survey. All responses were recorded anonymously with no way for any individual respondent to be identified. This research was reviewed and approved by the University of Pittsburgh Institutional Review Board in the exempt category.
Embedded in the Survey were several questions about the physician's experience with botulinum toxin injections; questions can be found in Appendix S1. Physicians were asked to report on the primary botulinum toxin used, common dosing information, the role of localization, and the role of sedation and distraction in their practice. When queried on localization, physicians could choose up to 2 methods, and muscle groups were separated based on size and accessibility. Large muscles were defined as having clear anatomic landmarks (ie, biceps, hamstrings, quadriceps, gastrocnemius, and thenar), and small muscles as having less distinct anatomic landmarks (ie, posterior tibialis, finger flexors, wrist flexors, and toe flexors). The relationships between localization and the primarily used sedation techniques were further explored. During data cleaning, 3 responses for maximum dose per body weight and 2 responses for maximum total dose were excluded from analyses by the study team due to extreme deviance. Univariate statistics were employed to describe the outcomes of interest using IBM SPSS software (version 24.0; IBM Corp, Armonk, NY).
Results
In the original sample of 307 pediatric physiatrists, 235 respondents opened the survey. Excluded from analysis were 18 respondents who did not meet eligibility criteria; that is, not practicing pediatric physiatry (n = 2), identifying as trainees (n = 10), indicating they were retired from practice (n = 4), or reporting that they did not practice clinical medicine at all (n = 2). An additional 5 responses were excluded, as 3 people did not consent to the survey and 2 respondents chose not to complete the procedural questions. Of the remaining 212 physicians, 91% (n = 193) indicated that they perform botulinum toxin injections.
Characteristics of the pediatric physiatry respondents who perform botulinum toxin injections are presented in Table 1 . The majority of respondents were women (61.7%) and had a Doctor of Medicine (MD) degree (89.1%). The vast majority (95.3%) were board certified in Physical Medicine and Rehabilitation by the American Board of Physical Medicine & Rehabilitation and most (79.8%) were also subspecialty certified in Pediatric Rehabilitation Medicine. Thirty-one percent were certified in Pediatrics through the American Board of Pediatrics.
Botulinum Toxin Technique
Nearly all (93.3%) of pediatric physiatrists who perform neurotoxin injections report primarily using onabotulinumtoxinA. AbobotulinumtoxinA and RimabotulinumtoxinB were reported as primary botulinum toxin much less frequently (2.1% and 2.6%, respectively). No respondents reported using IncobotulinumtoxinA as primary.
The maximum reported dose per body weight of onabotulinumtoxinA ranged from 4 to 30 units/kg, with a median of 15 units/kg ( Figure 1A ). The most common maximum dose was 20 units/kg. The distribution of maximum total dose reported by respondents ranged from 200 to 1200 units with large mode of 400 units (Figure 1b) . The most common dilutions (respondents could choose more than 1) were 100 units/mL (70.6%) and 50 units/mL (40.6%), although a smaller number of physicians reported using 200 units/mL (6.1%). If the injections demonstrated effectiveness, most physicians reported that the earliest interval they would perform a repeat botulinum toxin injections was at 3 months (78.8%). A much smaller number of physicians reporting 4 months (6.1%), and 4 physicians (<2%) reported they would repeat at 2 months or less.
Role of Localization
The most commonly reported intended injection site for botulinum toxin was "in multiple sites spread throughout the muscle" (67.9%). Other methods included "one site of the muscle at the motor point" (17.1%), "one site of the muscle, but not necessarily the motor point" (8.3%), and "other" (5.6%). When injecting large muscles (as defined above), the majority of respondents localized using anatomic guidance (75.6%). To a lesser extent, they also reported using electromyography or electrical stimulation, often referred to as estim (50.8%), ultrasound (14.0%), and/or target muscle stretch with needle in place 13.5%). Target muscle stretch is inserting the needle into the target muscle and then either passively or actively performing range of motion of the muscle and seeing the needle move as the target muscle is moved. When injecting small muscles, the majority of respondents typically localized using electromyography or electrical stimulation (73.6%). Anatomic guidance (49.2%), ultrasound (21.8%), and/or target muscle stretch with needle in place (13.0%) were reported less frequently.
Role of Sedation and Distraction
Sixty-five percent of pediatric physiatrists report using sedation, of any type, for botulinum toxin injections (n = 126). Of those physicians, 38.9% reported general anesthesia as most commonly used, but physicians also reported enteral or nasal anxiolytic with the patient awake (26.2%), conscious sedation (21.4%), or nitrous oxide (11.1%) as the most common. Forty-nine percent of pediatric physiatrists use general anesthesia or conscious sedation infrequently (in 30% or less of all injections completed), but there were also physicians (27.0%) who use it during the vast majority of cases (70%-99% of injections). A small minority (1.6%; n = 2) of pediatric physiatrists reported using general anesthesia for 100% of the botulinum toxin injections they perform.
Respondents also identified indications for using conscious sedation or general anesthesia (physicians could choose all that apply). Of the physicians using any sedation technique, common indications were the patient being unable to tolerate the procedure without sedation (84.9%), parent or patient requesting sedation (64.3%), coordinating the injections along with another procedure that required sedation (56.3%), and considering it unsafe to do the procedure without sedation (56.3%). Seventeen percent of the sample reported "injections are routinely done under sedation" as an indication. Commonly used adjunctive measures by pediatric physiatrists included movies or electronics for distraction (74.6%), topical anesthetic spray applied during the procedure (74.1%), and topical anesthetic applied before the procedure (69.4%). Physicians performing injections also reported using a designated person (64.8%) or toys (ie, bubbles, stress balls; 58.0%) for distraction. Only 3.1% (n = 6) of physicians reported using no adjunctive measures.
Combined use of sedation and localization
To further elucidate the role of sedation in relation to the complexity of the procedure planned, Figure 2 diagrams the relationship between the most common sedation technique (as reported by each physician) and typical mechanisms for localization. Localization techniques were distinguished based on use in small muscles only (SMO), large muscles only (LMO), or both small and large (SM&LM). As described above, physicians could choose up to 2 methods for localization for each muscle type.
Pediatric physiatrists tended to use similar techniques for both large and small muscles. However, for physicians completing botulinum toxin injections using anatomic guidance, SM&LM were most frequently completed awake or with enteral or nasal anxiolytics (n = 23). Electrical stimulation was more commonly used for SMO (n = 26) or SM&LM (n = 74) regardless of the primary sedation type, and rarely used by providers when injecting LMO (n = 4).
Significantly fewer physicians used ultrasound (n = 28) for localization regardless of sedation technique; however, when using ultrasound, the majority of physicians reported general anesthesia as the primary sedation technique (n = 15). Ultrasound was used for SMO (n = 11) or SM&LM (n = 17), but not for LMO muscle types.
Discussion
The objective of this project was to describe the current practice techniques when using botulinum toxin among pediatric physiatrists. Responses demonstrated that OnabotulinumtoxinA is currently the most frequently used botulinum toxin by pediatric physiatrists. This survey identified 3 areas of large variability among providers performing botulinum toxin injections in children: the technique used for botulinum toxins including target site for injection and volume of preparation, the localization techniques for injections, and the types of sedation used for these procedures. Each of these areas deserves attention and examination as these all have implications for the overall safety and clinical effectiveness of botulinum toxin injections in pediatric patients.
In terms of the technique performed to identify the site in the muscle for injection, 2 approaches are described in the literature: isolating the motor point or distributing the pharmaceutical throughout the muscle [19, 20] . Based on the results of this survey, the majority of pediatric physiatrists are distributing onabotulinumtoxinA throughout the muscle with a much smaller percentage trying to inject at the motor endplate or motor point. This survey found the 2 most common dilutions currently used in practice to be 100 units in 1 mL normal saline or 100 units in 2 mL of normal saline. Currently there are no pediatric outcome comparisons in the literature to guide decision making between different dilutions.
For localization, this survey demonstrated the majority of pediatric physiatrists were performing botulinum toxin injections of large muscles as well as small muscles using anatomic guidance or electrical stimulation. In small muscles, ultrasound was also used in a much lower percentage. This raises the question of the need for additional studies specific to pediatrics using different localization techniques to determine if any demonstrates improved outcomes.
When considering the use of sedation, procedural options exist for general anesthesia, conscious sedation, nitrous oxide, enteral anxiolytic medications and distraction only techniques for many pediatric procedures, but no comparison literature is available for use with botulinum toxin injections [21] [22] [23] [24] . One notable finding from the survey was that nearly 20% of botulinum toxin injections completed by those who use sedation for their injections were reported to be routinely completed under sedation. This reveals that without compelling reason for each individual case, a child is being subjected to the potential risks of sedation, as well as the increased time in clinic or the hospital and expense associated with sedation. General anesthesia use in the pediatric population has been investigated in 2 studies (one retrospective [25] and one systematic review with meta-analysis [26] ) and stated to have a potential link to attention deficit hyperactivity disorders or increased risk for adverse neurodevelopmental outcomes even after adjusting for comorbidities such as lower birth weight and gestational age. However, in a third sibling-matched cohort study, there was no difference in IQ score at the time of follow-up [27] . The duration of anesthesia reported was longer (45-115 minutes), compared to the time it typically takes to complete botulinum toxin injections, which is likely an important difference. In addition, medications given to provide anxiolysis can cause respiratory depression [28, 29] and increase the risk of aspiration [30] .
Although general anesthesia and conscious sedation as well as medication for anxiolysis come with risks, there are also risks to completing the procedure without any medications for comfort. Performing repeated procedures on a child with procedural anxiety may increase their distress with these or other procedures [31] , and there is no research regarding which techniques reduce procedural anxiety among children undergoing botulinum toxin injections. The long-term effects of sedation medications, both those for general anesthesia and conscious sedation, on a developing brain, and the potential for repeated events, warrants caution and further investigation. A future assessment is warranted to determine the factors that are driving this decision. Are they resource based, institutional policy based, personal preference/experience, or felt necessary because of localization technique or something else entirely?
There have been 2 publications on botulinum toxin in children with cerebral palsy written as a consensus statement or a guideline for approach [32, 33] . The first, a guideline, written in 1997 recommends a maximum dose of OnabotulinumtoxinA at any one visit be 12 units/kg body weight up to a maximum dose of 400 units as well as a maximum of 400 units injected during a 3-month interval. The maximum dosage for an individual large muscle was 3 to 6 units/kg body weight and a small muscle 1 to 2 units/kg body weight, and a maximum of 50 units per injection site. Typical dilutions were 100 units to 1 to 2 mL normal saline. The number of injection sites reported is based on the size of the muscle and accessibility without other discussion of injection technique [32] . The European consensus, published in 2006, reported using OnabotulinumtoxinA up to 12 to 30 units/kg body weight depending on single-versus multimuscle approach with a total dose of 400 to 600 units. Additional recommendations included use of an accurate localization technique, but an exact technique was not specified [33] .
Although there are similar consensus statements for botulinum toxin injections used for patients of adult ages, there are no published data identifying the techniques of physiatrists who perform these procedures to compare our findings. Despite 2 pediatric consensus statements, our survey found that there remains significant variability within pediatric physiatry in many dimensions of this common procedure. As a result, patients and families likely experience significant practice variability of botulinum toxin injections among pediatric physiatrists.
Limitations
This study evaluated practice patterns and, therefore, does not capture the clinical outcomes of the various reported techniques. Because only a small percentage of providers use AbobotulinumtoxinA, RimabotulinumtoxinB, and IncobotulinumtoxinA as their primary botulinum toxin, practice patterns for these medications were not reported. There was also a small amount of missing data (2%) and some responses were excluded from analyses due to extreme deviance (indicating error in the interpretation of the item). For example, answers of 400 to 500 units for the maximum number of units/kg body weight used in a single treatment course were excluded as these are consistent with total maximum dose responses and considerable outliers based on body weight. Similarly, responses of 12 to 16 units for the maximum total dose were excluded as these are consistent with maximum dose per kilogram body weight and considerable outliers for maximum total dose. A few of the responses to the dosage questions were qualified with the age range of patients typically treated, and because these data were not asked of all survey respondents they were excluded. Despite these limitations, this study has significant strengths including reporting on the largest sample of pediatric physiatry practice techniques to date and a robust response rate at 76.5%.
Future Research
This study highlights the need for additional research in the following areas: comparing outcomes of botulinum toxin injections in pediatrics by dosing, formulation, dilution, localization, and sedation technique used as well as taking into consideration any adverse events and procedure tolerance. It would be helpful to understand what distraction or sedation techniques result in the best procedural anxiety control for children. It is also important to identify the underlying factors influencing variability as well as the motivators that influence the decision regarding these variables. Future research in these areas are necessary to optimize practice and obtain the best outcomes for patients receiving neurotoxin injections.
Conclusion
This survey represents a current snapshot of practice techniques for botulinum toxin injections in pediatric patients among practicing pediatric physiatrists. Overall, the results highlighted significant variability present in one common procedure and indicated important areas for future study.
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